ANDA 213352, held by Nephron. Verapamil Hydrochloride.
As of Nov 15, 2026, ANDA 213352 (Verapamil Hydrochloride), held by Nephron, was first approved by FDA on Mar 17, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 17, 2020 | Original application | Approved | None posted |
| Verapamil Hydrochloride10MG/4ML (2.5MG/ML) · solution;intravenous | Verapamil Hydrochloride | Rx |
| Verapamil Hydrochloride5MG/2ML (2.5MG/ML) · solution;intravenous | Verapamil Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
